Africa Applauds Price Cut for New HIV Prevention Medication
Long-acting HIV injection at $40 could reshape prevention — if the world can deliver it
A potentially seismic shift in HIV prevention is quietly taking shape: a twice-yearly injectable drug, lenacapavir, has won backing from global health partners and is slated to be available to more than 100 low- and middle-income countries within the next two years — at a price that would make it accessible to millions.
Under an agreement brokered by the Clinton Health Access Initiative with support from the Bill & Melinda Gates…